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Abstract The development of bio-based nanostructures
as nanocarriers of bioactive compounds to specific body
sites has been presented as a hot topic in food, pharma-
ceutical and nanotechnology fields. Food and pharmaceu-
tical industries seek to explore the huge potential of these
nanostructures, once they can be entirely composed of
biocompatible and non-toxic materials. At the same time,
they allow the incorporation of lipophilic and hydrophilic
bioactive compounds protecting them against degradation,
maintaining its active and functional performance. Never-
theless, the physicochemical properties of such structures
(e.g., size and charge) could change significantly their
behavior in the gastrointestinal (GI) tract. The main chal-
lenges in the development of these nanostructures are the
proper characterization and understanding of the processes
occurring at their surface, when in contact with living
systems. This is crucial to understand their delivery and
absorption behavior as well as to recognize potential
toxicological effects. This review will provide an insight
into the recent innovations and challenges in the field of
delivery via GI tract using bio-based nanostructures. Also,
an overview of the approaches followed to ensure an ef-
fective deliver (e.g., avoiding physiological barriers) and to
enhance stability and absorptive intestinal uptake of
bioactive compounds will be provided. Information about
nanostructures’ potential toxicity and a concise description
of the in vitro and in vivo toxicity studies will also be
given.
Keywords Nanoparticles  Bioactive compounds 
Gastrointestinal tract  Intestinal absorption  Absorption
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Introduction
Food industry is constantly looking for novel technologies
to improve the nutritional value, taste, flavor, shelf life and
food safety of their food products. However, addition of
micronutrients and bioactive compounds to food products
is a major technological challenge. Many of these bioactive
ingredients are chemically and physically vulnerable to
production conditions and to digestion process. These may
lead to detrimental effects on food properties, particularly
changing food sensory properties and limiting bioactive
compounds efficiency (i.e., bioaccessibility and bioavail-
ability). In fact, a considerable number of bioactive com-
pounds showed irrelevant or unsatisfactory therapeutic
effects when orally administered in a free state once they
were rapidly degraded losing their bioactivity [47].
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In recent years, nanotechnology has become an answer
to many of these problems, as it offers the ability to de-
velop delivery structures (at submicron/subcellular size)
for bioactive compounds’ (e.g., vitamins and antioxidants).
This enables protecting bioactive compounds against
degradation and controlling delivery at specific sites in the
body [169].
Gastrointestinal (GI) tract is a particularly attractive
targeting site due to its large surface area, in addition to its
high potential to absorb (e.g., nutrients, bioactive com-
pounds) and deliver it through the bloodstream [160]. One
of the advantages of site-specific delivery to the GI tract
will likely be for treatment of local conditions of the gut
since there is a direct contact with the material being
ingested. Such gut health conditions includes chronic in-
flammatory diseases (e.g., Crohn’s disease and ulcerative
colitis), gastric and duodenal ulcers, GI infections and
gastric and colon cancers [127]. However, GI tract delivery
of bioactive ingredients is a great challenge owing to pe-
culiar physiological barriers and physicochemical proper-
ties, such as metabolism and gastrointestinal instability. An
ideal GI tract delivery nanostructure system should be ca-
pable of (1) maintaining its integrity until it reaches the site
of absorption, (2) attaching itself to the GI mucosa through
specific interactions, releasing the bioactive compound at
the target absorption site, and (3) holding inside the GI
tract independently of its environmental conditions [53].
Each one of these issues is of utmost importance for an
efficient bioactive compound delivery strategy.
Recent advances in nanotechnology-based delivery
systems showed potential for achieving these goals. Many
of the polymeric materials used in the development of
nanostructures for bioactive compounds delivery are nat-
ural, non-toxic, biocompatible and biodegradable such as
proteins, polysaccharides and lipids [9, 46]. With the de-
velopment of novel technologies, including permeability
enhancers, it is expected that the number of bioactive
compounds safely and efficiently delivered into the GI tract
mucosa will increase.
At the same time, it is noteworthy that materials ma-
nipulation at the nanoscale can lead to the formation of
novel structures with potential toxic characteristics. Their
dimension allows penetrating biological tissues, which
could cause the disruption of their normal function or cell
death. Examples of toxic effects include tissue inflamma-
tion and modification of cellular redox balance [6]. Current
knowledge on the toxicity of macro- and microstructures
may not be reliable in predicting toxic forms of nanos-
tructures, and thus further studies to evaluate ‘‘nan-
otoxicity’’ are mandatory.
The present review will focus in the current research on
bio-based nanostructures for bioactive compounds delivery
that could improve GI tract interactions and absorption.
The review will be divided in five main sections:
1. An overview of the main challenges and characteristics
of the GI system and how those may influence the
passage and integrity of nanostructures will be pre-
sented. In addition, the potential transport mechanisms
of these nanostructures once they reach the intestine
will be also discussed;
2. The bio-based nanostructures that are currently being
developed and their main physicochemical character-
istics will also be highlighted. Each different nanos-
tructure has been further subdivided according to its
material, structural design and function. Consequently,
strategies to improve these nanostructures in order to
fulfill their primary function of transporting bioactive
compounds during transit and absorption processes in
the GI system will be addressed;
3. The separation, purification and characterization tech-
niques of bio-based nanostructures following digestion
and absorptionwill be highlighted. These techniques can
be of great help for researchers providing a new insight
on the behavior and integrity of developed nanostruc-
tures during their passage through the GI tract;
4. A thorough understanding of the interactions and
potential risks of bio-based nanostructures with
biological systems (e.g., cells of the immune system)
using in vitro and in vivo models will be also
addressed;
5. Lastly, a brief section on regulation will mention the
problem of missing regulatory definitions and global
consistency concerning nanostructures.
Delivery Challenges in GI Tract
Overall, the main GI tract function is to digest (through a
dissolving and breaking down process) food into molecular
forms that can be absorbed, i.e., that are able to cross the
intestinal epithelium.
During the passage through the GI tract, nanostructures
find several physiological and morphological barriers (e.g.,
enzymes present in the gut lumen and in brush border
membrane, the mucus layer and epithelial cell lining) that
play a key role in the bioactive compounds delivery
(Fig. 1) [47]. Also, at the nanometer scale, the biological
fate of the delivery systems and bioactive compounds in-
corporated within may be altered [104]. In contrast to
microparticles that are too large to pass through epithelium
and must release the bioactive compounds in the GI tract,
nanostructures can be taken up and cross the intestinal
barrier [31].
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The uptake of nanostructures in the GI tract and the
consequent bioactive compounds delivery depends on dif-
fusion and accessibility through mucus, initial contact with
the gut epithelium and various uptake and translocation
processes [13, 117].
GI Barriers
The GI system comprises the GI tract (mouth, pharynx,
esophagus, stomach, small intestine and large intestine)
and accessory organs (salivary glands, liver, gallbladder
and pancreas) that secrete substances into the GI tract via
connecting ducts [166].
Immediately after the ingestion, nanostructures are
mixed with saliva being influenced by digestive enzymes,
pH, ionic strength and temperature changes. Therefore,
even at this early stage of digestion, the initial size and
interfacial characteristics of bio-based nanostructures can
be changed.
After reaching the stomach, ingested nanostructures are
mixed with enzymes such as gastric lipases that initiate
lipid digestion and proteases that initiate protein digestion.
The nanostructures are exposed to a highly acidic medium
(pH 1–3) and to a peristalsis process. This process consists
in an advancing walls contractile wave of a flexible conduit
forcing their contents to move forward [77]. At this stage,
original interfacial characteristics (e.g., charge and thick-
ness) of ingested nanostructures may be changed, as well as
their size (i.e., may no longer be at nanometric scale) due to
pH, ionic composition changes and digestive enzymes
[104].
Then, ingested structures move to the small intestine,
where most of absorption occurs. At this stage, the
nanostructures are mixed with bile salts, phospholipids,
pancreatin, colipase and bicarbonate, and mixture pH in-
creases, being almost neutral. The digestive enzymes pre-
sent may hydrolyze the components that constitute the
nanostructures (e.g., pancreatic lipase hydrolyzes triacyl-
glycerols into monoacylglycerols and free fatty acids, and
proteases hydrolyze proteins into peptides and amino
acids). Within the small intestine, besides the digestion
process, other phenomena can occur (e.g., particle aggre-
gation or competitive adsorption process) resulting in
changes in particle size and interfacial characteristics of
nanostructures (Fig. 1) [127].
After digestion, the small molecules produced move
from the lumen of the GI tract across a layer of epithelial
cells into blood or lymph [166]. The small intestine is di-
vided into three segments, i.e., duodenum, jejunum and
ileum, designed to maximize absorption. Human intestinal
epithelium is composed of villi that increase the total ab-
sorptive surface area to about 300–400 m2 [47]. Villi are
covered by enterocytes (absorptive) and goblet cells (mu-
cus secreting), which are interspersed with follicle-associ-
ated epithelium (FAE). FAE is the interface between the
luminal environment and the lymphoid tissue associated to
the gut composing Peyer’s patches [124]. These lymphoid
regions are covered with M cells which play a significant
role in absorption of nanostructures and bioactive com-
pounds, since they are relatively less protected by mucus
and have a high transcytotic capacity [124]. The mucus
layers, which are mainly composed of gel-forming mucins
(glycoproteins), are considered to be significant barriers to
nanostructures penetration [82]. Mucus is continuously
secreted to protect epithelial surface against pathogens by
rapidly removing foreign particles from the GI tract and to
Fig. 1 Potential physiological
and physicochemical changes of
nanostructures within the
digestive tract from
consumption stage to body
elimination. Adapted from
Szakal et al. [154]
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lubricate the epithelium as material passes through.
Therefore, nanostructures residence time decreases being
unable to penetrate the mucus layer [47].
In addition to the GI mucus layer, the microbiota within
the gut can also play an important role on the interaction
with nanostructures. GI microbiota is responsible for a
series of activities such as protection against potential
pathogens, digestion of polysaccharides (e.g., chitosan and
pectins), enzymatic hydrolysis, biosynthesis of vitamins (K
and B), modulation of immune system and regulation of fat
storage [10, 78]. Adherence of microbiota to gut wall can
result in biofilm formation due to exopolymers secretion
and subsequent gut protection from contact with nanos-
tructures [113].
Transport Mechanisms
GI tract barriers, in particular intestinal epithelium, highly
limit absorption and consequent efficient delivery of
nanostructures (i.e., entering bloodstream). Intestinal ep-
ithelium acts as a selective barrier that tightly mediates
transport from intestinal lumen into the bloodstream [161].
There are two main transport mechanisms of biomolecules
across intestinal epithelium: (1) between cells via tight
junctions (TJs)—paracellular route and (2) through in-
testinal membrane cells—transcellular route. Transport by
paracellular route is mainly passive, whereas transcellular
pathway includes passive diffusion, active carrier-mediated
and endocytosis transport mechanisms (Fig. 2) [92].
Each pathway will depend on absorbing molecule phy-
sicochemical characteristics (e.g., size, charge and inter-
facial chemistry), physical (e.g., TJs and lipid composition)
and biochemical barriers (e.g., presence of enzymes, efflux
and influx transporters) of cell membrane, which are able
to metabolize or expel the biomolecules from the cell
[160]. In the scope of studying transport mechanisms of
nanostructures, two types of intestinal cells are mainly
considered: enterocytes and M cells, which are the primary
intestinal cells for the transport of a wide range of nanos-
tructures [31, 61]. It is probable that both paracellular and
transcellular routes contribute to the absorption of a single
biomolecule or of more complex systems, i.e., bio-based
nanostructures [57, 176].
In the literature, it is possible to find several research
reports where bio-based nanostructures were able to cross
the intestinal barrier via paracellular transport mechanism
(Fig. 2), e.g., glyceride-based colloidal nanosystems, as
delivery system for doxorubicin [76], nanohydrogel as
carrier of salmon calcitonin [163], nanoparticles self-
assembled by chitosan and PGA for delivery of tea cate-
chins [156].
On the other hand, bio-based nanostructures can be
absorbed by simple transcellular mechanism (passive
transport) or by active carrier-mediated transport (Fig. 2).
Certain nanostructures can also enter the cell through en-
docytosis (phagocytosis or pinocytosis) [74]. Guri et al.
[58] showed that curcumin-loaded solid lipid nanoparticles
were able to rapidly permeate through Caco-2 cell mono-
layer using simple diffusion mechanism. Feng et al. [50]
demonstrated that clathrin-dependent endocytosis played
an important role in transcellular transport of chi-
tosan/carboxymethyl chitosan nanohydrogels carrying the
anticancer compound, doxorubicin hydrochloride. Inter-
nalization of nanostructures by pinocytosis includes
Fig. 2 Schematic representation of the different pathways for
intestinal epithelium transport: a Paracellular Transport (restricted/
limited to small hydrophilic molecules with molecular mass
\100–200 Daltons that can cross tight junctions of the epithelial cell
layer); Transcellular b carrier-mediated (carriers recognize target
molecules through membrane receptors and transport them across the
GI epithelium), c receptor-mediated (molecules act either as a
receptor-specific ligand for surface-attached receptors or as a receptor
for surface-attached ligands), d Endocytosis (particles are transported
through the cells by vesicular transport mechanism) and e M cell-
mediated transport (M cells, located within the epithelium of Peyer’s
patches, possess a high endocytosis capacity and could transport a
wide variety of nanomaterials)
494 Food Eng Rev (2015) 7:491–513
123
receptor-mediated endocytosis (RME) [136]. Teng et al.
[158] reported that curcumin transport using folic acid/soy
protein nanoparticles was enhanced. They assume that folic
acid could have targeted folate receptor protein, thus im-
proving curcumin REM transport. Other well-known re-
ceptor is lactoferrin (Lf) receptor, expressed on apical
surface of intestinal cells. Zhang et al. [180] studied the
absorption mechanism of gambogic acid-Lf nanoparticles
(GL-NPs), where Lf receptor seems to play an important
role in the GL-NPs transport through the membrane.
After providing an overview of GI tract challenges that
need to be addressed when encapsulating bioactive com-
pounds, the next section will describe how food-grade
nanostructures can be designed to meet these challenges.
Features of Bio-Based Nanostructures for GI Tract
Delivery
Effects of Nanostructures’ Physicochemical Properties
on Absorption
Absorption, metabolism, distribution and excretion pro-
cesses depend on nanostructures’ composition and physi-
cochemical properties such as size, shape, charge and
hydrophobicity. Nanostructures physicochemical charac-
teristics determine their fate once they have entered ep-
ithelium cell. They may be (1) digested by cellular
enzymes into their constituent parts which may be ab-
sorbed; (2) transported directly out of the cell, and into the
blood or lymph systems; or (3) accumulated within specific
locations in the cell [104].
Nanostructures particle size significantly affects their
absorption and biodistribution. It has been found that par-
ticle size can affect efficiency and pathway of cellular
uptake once it influences structure adhesion and interaction
with cells [98]. Nanostructures have shown to increase GI
uptake and the level of translocation to lymphatic organs,
when compared to microstructures [32]. For example,
biodegradable structures of different sizes were produced
using PLGA and bovine serum albumin as a model protein.
Nano- and microstructures uptake was evaluated in situ
with a rat intestinal loop model. Compared with larger
particle sizes, uptake efficacy of 100 nm particles by the
intestinal tissue was found to be 15- to 250-fold higher,
depending on the type and location of tissue collected.
Also, histological evaluation of tissue sections showed that
100 nm particles diffused through submucosal layers,
while microparticles were predominantly localized in ep-
ithelial layer tissue [32].
It has been demonstrated that cells can take up nanos-
tructures with various shapes including spheres, rods, tubes
and sheets. However, there is some controversy about the
influence of particle shape on nanostructures translocation.
Thus, efforts should be done to clarify this effect [63].
When comparing spherical and rod-like nanostructures
cellular uptake, it was found that spherical nanostructures
were more easily endocytosed by HeLa cells [21]. On the
other hand, Alemdaroglu et al. [5] investigated whether the
shape of micelle aggregates influences the internalization.
They observed that rod-like polymeric particles were taken
up 12 times more efficiently than their spherical counter-
parts, although they were composed with the same
constituents.
Nanostructures cellular uptake can be divided in two
steps: first, a binding step on the cell membrane and sec-
ond, an internalization step. Nanostructures’ binding to cell
membrane seems to be dependent on nanostructure surface
charge. However, there is not an agreement on the optimal
charge for translocation. Cationic nanostructures have been
shown to be absorbed more readily than anionic ones. The
interactions between anionic membrane and cationic
nanostructures facilitate their binding to cell membrane and
consequently their uptake. It has been shown that cationic
polymers such as chitosan can form nanostructures that
maintain a prolonged contact time with the intestinal layer.
This leads to a larger absorptive surface and subsequently,
enhanced absorption rates [95]. Contrarily, Patil et al. [118]
showed that nanostructures with the highest negative
charge values have the highest cellular uptake compared
with other formulations with less negative or positive
surface charge. The authors concluded that the high cel-
lular uptake of negatively charged nanostructures is related
firstly to the nanostructures non-specific adsorption to
cell membrane, and secondly, to nanostructures’ clusters
formation.
Particle absorption is also believed to depend on
nanostructure surface hydrophobicity. Although there is
not a very clear tendency, uptake of nanostructures pre-
pared from hydrophobic polymers seems to be higher than
that of structures with more hydrophilic surfaces [70].
Norris and Sinko [114] suggested that increasing hy-
drophobicity leads to an increase in permeability through
mucin, but also to a decrease in the translocation across the
cell interior, which has a more hydrophilic environment.
Bio-Based Nanostructures Delivery Systems
Multifunctional nanostructures using biomaterials with
distinctive architectures have been designed and evaluated
for bioactive compound delivery applications [68].
Biopolymer architecture, composition and stability are
important factors which will influence bioactive compound
delivery carriers’ effectiveness. Moreover, biopolymer
nanostructure dimensions change its functional attributes in
foods and GI tract. For instance, nanostructure architecture
Food Eng Rev (2015) 7:491–513 495
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influences physicochemical properties of foods (e.g., sta-
bility), encapsulation characteristics (e.g., loading and re-
lease), and behavior within the Gl tract (e.g., interaction
with the environment and degradation) [2]. Therefore, ap-
propriate nanostructures need to be designed rationally
according to specific applications and needs.
Most of the publications focus on the synthesis and
study of core–shell structures [23]. These structures are
obtained from polymers of different sizes and shapes and
can be functionalized with stimuli-responsive polymers
(e.g., proteins) [110]. The most common shape of food-
grade nanostructures suitable for encapsulation is spheroid
(Fig. 3). Nanoemulsions, for instance, tend to be ap-
proximately spherical, and may have a variety of internal
organization, such as homogeneous or dispersion struc-
tures, depending on the material and preparation method
used [68].
Multilayer nanostructured systems could also be pro-
duced with multiple layers of emulsifiers and/or polyelec-
trolytes by the layer-by-layer (LbL) technique (Fig. 3).
Additionally, hollow multilayered nanostructures can be
obtained using colloidal templates (e.g., polystyrene
nanoparticles). After LbL deposition procedure, the tem-
plate could be dissolved using an acid or a solvent. These
nanostructures can be applied as delivery systems of
bioactive compounds, being those compounds either
entrapped inside the core or adsorbed on the surface of
nanocapsule [15].
In this section, a selected group of bio-based nanos-
tructures (i.e., nanoemulsion, nanohydrogel and nanocap-
sules) that have been most commonly used in bioactive
compounds GI tract delivery applications are reviewed.
Nanoemulsions
Oil-in-water nanoemulsions are a mixture of two immis-
cible liquids, where a thin interfacial layer is created due to
the adsorption of the emulsifier molecules surrounding the
oil droplets. The emulsifier promotes the dispersion of the
oil phase in the continuous phase either using low-energy
or high-energy techniques [1, 146]. In water-in-oil na-
noemulsions, the oil is the continuous phase, where the
emulsifier surrounds the water droplets (disperse phase).
The emulsifiers can also be dispersed in the continuous
phase or in the dispersed phase, depending on their hy-
drophilic–lipophilic balance [75].
Due to the emulsifier ability to decrease the interfacial
tension between two immiscible liquids, emulsifiers play a
major role in the formation of the nanoemulsions, creating
an interfacial layer able to protect the oil droplets [146].
Thickening agents such as starch, flour and gums can also
be used to stabilize emulsions. These agents act by
Nanoemulsionsmaterial:
-Core
NANOEMULSIONS NANOHYDROGELS NANOCAPSULES
Nanohydrogel Nanocapsule Mullayered
Nanocapsule
: monoacylglycerols, 
triacylglycerols, waxes, mineral oils, oil-
soluble vitamins, nutraceucals
-Shell: Surfactant, phospholipids, 
proteins
Main role/characteriscs:
-Carrier of lipophilic molecules;
-Protecon of sensive molecules;
-Increased bioavailability
Nanohydrogelsmaterial:
-Proteins (whey-proteins, gelan)
-Polysaccharides (carrageenan, pecn, 
dextran)
Main role/characteriscs:
-Carrier of hydrophobic and hydrophilic
molecules;
-Protecon of chemically labile bioacve 
ingredients;
-Controlled release
Main role/characteriscs:
-Carrier of hydrophobic and hydrophilic
molecules;
-Protecon of sensive molecules;
-Controlled release
Nanocapsulesmaterial:
-Core: polystyrene nanoparcles, 
vitamins, carotenoids, nutraceucals
-Shell: protein (zein, casein), 
polysaccharides (chitosan, alginate, 
cellulose)
Mullayered
Nanoemulsion
Nanoemulsion
Mullayered
Nanohydrogel
LbL assembly
(biopolymers)
LbL assembly
(biopolymers)
LbL assembly
(biopolymers)
Fig. 3 Representative bio-based nanostructures for bioactive compounds gastrointestinal tract delivery, and their main characteristics [15, 68,
69, 71, 103, 110]
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increasing the viscosity of the medium, which helps sta-
bilizing the suspension of droplets of the dispersed phase
preventing them from moving around and coalescing [34].
Nanoemulsion normally presents a core–shell structure
and may be manufactured from a great variety of food-
grade ingredients (Fig. 3). For example, the core may be
formed from nonpolar components, including monoacyl-
glycerols, diacylglycerols, triacylglycerols, waxes, mineral
oils, oil-soluble vitamins and nutraceuticals [103]. The
shell is typically formed from one or more surface-active
components, including small molecule surfactants, phos-
pholipids, proteins (e.g., whey proteins) and polysaccha-
rides (e.g., chitosan) [135]. The materials that comprise the
core and shell may be more or less digestible within dif-
ferent regions of the human GI tract, which plays an im-
portant role in determining their biological fate.
Nanoemulsion technology can be used to encapsulate,
protect and deliver lipophilic bioactive compounds, such as
essential oils (e.g., x-3-rich oils), antioxidants (e.g., quer-
cetin), antimicrobials (e.g., thymol) and vitamins (e.g.,
vitamin A) [139]. Nevertheless, hydrophilic and am-
phiphilic bioactive compounds can also be incorporated
[11]. This technology allows improving the solubility and
bioavailability of these compounds, also preventing the
degradation against light and oxidation using only food-
grade ingredients, by simple process operations (Table 1).
By controlling the composition and structure of na-
noemulsions, it is possible to create different rheological
properties and release profiles in response to environmental
triggers [105].
The main challenges in nanoemulsion technology are: (1)
proper selection of the emulsifier, due to the limited number
of food-grade emulsifiers that can be used in its formation,
restricting the ability to create nanoemulsions with different
release characteristics; (2) their physical instability under
environmental stresses, such as freeze-thawing, pH, salt,
heating, dehydration and chilling; (3) limited control over
oxidation of the bioactive compounds due to the very thin
interfacial layer; and (4) ability to provide better protection
and stability for encapsulated bioactive compounds during
the GI passage (Table 1) [38, 105]. One strategy aimed at
overcoming these limitations is to create one or more layers
of a polyelectrolyte surrounding the nanoemulsion through
the LbL technique [59]. This strategy may offer potential
advantages due to: (1) the ability to control the order and
location of multiple polymer layers with nanoscale preci-
sion; (2) the ability to define the concentrations of incor-
porated materials simply by varying the number of
polyelectrolyte layers [153]; and (3) possibility to use a wide
range of polymers, which increase its potential application.
Biopolymers (such as proteins and polysaccharides) are of
high interest because of their unique characteristics:
naturally available, nontoxic and biocompatible. Conse-
quently, an exceptionally broad range of biopolymer com-
ponents, morphological characteristics, functional
responses, variety of interactions and versatility in assembly
approaches enhance the use of LbL technique [29]. LbL
technique consists in the deposition of polyelectrolytes on
charged surfaces due to strong electrostatic attractions be-
tween the surface and the charged polyelectrolytes, thus
building a ‘‘new’’ layer. This technique also allows that
further layers can be built by simple addition of oppositely
charged polyelectrolytes in solution, promoting the ad-
sorption of the polyelectrolytes on the top of the first layer.
Repetition of this adsorption steps leads to the formation of
multilayers (Fig. 3) [59]. The number of layers will be de-
fined by the final application of these systems [87, 122].
Charged nanoemulsions can be used as substrate, allowing
the development of a new system (i.e., multilayer na-
noemulsion) [105]. Salminen and Weiss [137] showed,
through the production of a whey protein–pectin multilayer
nanoemulsion, that it is possible to improve its stability to
different environmental stresses: salt (0–500 mMNaCl) and
heat (40–90 C, 30 min). These authors demonstrated that
emulsions saturated with biopolymer complexes exhibited
good stability (no aggregation) to salt (up to 200 mM) and
heat (up to 90 C) at pH 3.5–4.5. However, the biopolymer
complex layer adsorbed to the emulsion interface was not
able to prevent instability after freeze-thawing cycles
(-20 C, 22 h). Li and McClements [86] built an alginate
layer on Tween 20 and b-lactoglobulin nanoemulsions. This
layer reduced lipid digestion inhibiting lipase access to the
lipid in the nanoemulsion.
The modification of nanoemulsion composition and
structural characteristics such as particle size, emulsifier
and oil and polymer type can change the digestion rate.
Therefore, the effects of these characteristics are being
widely studied [87, 122]. Li et al. [87] examined the in-
fluence of chitosan (intermediate layer), pectin and alginate
(outer layer) layers in the digestibility of the multilayer
system using an in vitro digestion model. They evaluated
the effect of composition and structure of the biopolymer
on the digestion rate, accessing the release of free fatty
acids from the nanoemulsions and multilayer nanoemul-
sions (first and second layer). Nanoemulsions were di-
gested between 30 and 40 min, which show that lipase
adsorbed to the nanoemulsions promotes the lipolysis of
triacylglycerols. For the multilayer nanoemulsions the di-
gestion rate was significantly slower, where only 40 % of
the lipids where digested after the same time (i.e., 40 min).
The authors hypothesized that biopolymers layers protect-
ed the lipid droplets restricting the access of the lipase to
triacylglycerols, retarding the lipolysis reaction and there-
fore delaying the lipid digestibility.
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Pinheiro et al. [122] studied the effect of different charged
emulsifiers—Tween 20 (non-ionic), sodium dodecyl sulfate
(anionic) and dodecyltrimethylammonium bromide (ca-
tionic)—in the behavior of curcumin nanoemulsions during
in vitro digestion. Nanoemulsions were produced by high-
pressure homogenization, and an in vitro digestion model
was used. All emulsifiers used formed stable nanoemulsions
within the nanometric scale. Nevertheless, during simulated
digestion, all nanoemulsions increased their sizes, being this
attributed to aggregation, coalescence or flocculation due to
the action of digestive enzymes, as well as to changes in pH
and ionic strength. The emulsions producedwith the cationic
emulsifier were the least stable. The positive charge of the
cationic emulsifier may have promoted the adsorption of
anionic lipase and anionic bile salts to the oil–water inter-
face. The emulsifier type had also impact in curcumin
bioavailability. Nanoemulsions stabilized with the non-ionic
emulsifier increased curcumin bioavailability during diges-
tion time, which can be due to the formation of digestion
products (ability to formmixedmicelles). On the other hand,
the use of cationic emulsifier allowed achieving only a very
low bioavailability during simulated intestinal conditions,
i.e., emulsions became unstable, leading to phase separation.
Nanohydrogels
Nanohydrogels are three-dimensional hydrophilic or am-
phiphilic biopolymer nanosized networks that can swell
and hold a large amount of water. However, they are pre-
vented from dissolving due to their chemically or
physically cross-linked structure [19] (Fig. 3). The swel-
ling ability is attributed to the presence of hydrophilic
moieties groups (e.g., hydroxyl, carboxyl, ethers, amines
and sulfates) in the polymers forming the nanohydrogel
structure, which is responsible for the soft and pliable
characteristic of such nanostructure [120].
Bio-based nanohydrogels can be prepared from several
polysaccharides (e.g., alginate, chitosan, pectin, pullulan
and dextran) and proteins (e.g., whey proteins and colla-
gen) with different techniques; being the most commonly
used method the gelation process [164]. Gelation is a
process that typically encompasses two stages: (1) partial
unfolding of the native structure leading to dissociation of
intramolecular bonds that can be induced by several envi-
ronmental conditions (e.g., temperature) and (2) formation
of new bonds, leading to a progressively larger em-
branchment of molecules. The continuous cross-linking
increased the size of the ramified polymer chains (in
nanometer range) decreasing their solubility, which results
in the formation of a gel structure [133].
Their reduced size enables a controlled release of
bioactive compounds and improved bioavailability of those
compounds with poor absorption rates. Moreover, they
specified delivery to the associated tissues, reducing the GI
mucosa irritation caused by continuous contact with some
compounds, and assured their stability in the GI tract [116].
In addition, nanohydrogels allow overcoming some draw-
backs inherent to other nanostructures (e.g., preparation
procedure and relatively low loading capacity). They can
be produced without the interference of the bioactive
compounds and designed to spontaneously load bioactive
molecules. Electrostatic, van der Waals and/or hydropho-
bic interactions between bioactive compounds and polymer
matrix, during gel folding process, lead to formation of
stable nanostructures’ [15]. Furthermore, these structures’
ability to produce a response (e.g., swelling) to environ-
mental stimuli (e.g., temperature, pH, ionic strength or
enzymatic conditions) makes them crucial systems to de-
liver bioactive compounds locally to specific sites and at a
particular time in the GI tract [91]. On the other hand, these
structures may present some limitations if produced by
physical gelation. Once nanohydrogels contain labile bonds
in polymer networks, they are susceptible to be disrupted
under physiological conditions in the GI tract [62].
It is possible to find in the literature different works
reporting protein nanohydrogel’s ability to incorporate and
release hydrophilic and lipophilic bioactive compounds
such as drugs, unsaturated fatty acids, vitamins, as well as
peptides [152]—see Table 1. Depending on bioactive
compound characteristics, it is possible to obtain different
release mechanisms during digestion process. Hydrophilic
compounds release from a protein matrix by diffusion,
whereas lipophilic compounds are released mainly by en-
zymatic degradation of the protein matrix in the GI tract
[170]. Examples of bioactive compounds efficiently in-
corporated into bio-based nanohydrogels, techniques used
in their encapsulation and their main limitations are sum-
marized in Table 1.
One of the challenges of these nanostructures is to de-
liver encapsulated components at the desired point (e.g.,
mouth, stomach, small intestine and colon) without being
destroyed. Therefore, it is important to design and
manufacture biopolymer nanohydrogels with specific
compositions, which can be able to resist to severe envi-
ronmental conditions, for example, resistance to gastric
fluids, if nanohydrogel is designed to deliver a bioactive
compound in the colon. Nanostructures composed by
peptides or proteins have a high level of GI degradation by
digestive enzymes [37]. In order to preserve functionality
and integrity, nanohydrogels must resist to the harsh gastric
conditions (i.e., low pH and presence of digestive en-
zymes). A major drawback of these biopolymeric nanos-
tructures is their tendency to decrease their interfacial
surface area leading to the formation of aggregates [155].
One of the strategies for preventing aggregation or de-
struction include nanohydrogels coated with foreign
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coating agents and/or tailoring particle surface charges to
create separation through electrostatic repulsion (Fig. 3).
LbL assembly of polyelectrolyte multilayers has been
demonstrated on various templates, from hard and planar to
rigid particles, and more recently, to soft and porous tem-
plates, such as thermoresponsive nanohydrogels [175]. The
possibility of assembling any charged polyelectrolytes on
nanohydrogels shows their potential exploitation as
bioactive compound storage, transport, target and con-
trolled delivery system. Tan et al. [155] demonstrated the
successful preparation of coated nanohydrogels with en-
capsulated drugs using the LbL approach. These authors
observed that the initial burst release behavior observed in
nanohydrogels was minimized and eliminated by the in-
troduction of several polyelectrolyte layers. Through this
LbL approach, the permeability of nanohydrogels was al-
tered with each additional layer. These authors also con-
cluded that swelling behavior of coated nanohydrogels
decreased with increasing polyelectrolytes layers resulting
in a slower release of bioactive compounds. The applica-
tion of polyelectrolyte layers also shows to be a successful
technique to turn nanostructures more stable under
physiological conditions [165]. Interaction between
biopolymers, such as polysaccharide protein, also allows
producing nanohydrogels more resistant to gastric fluids.
Chen and Subirade [18] developed a biopolymeric
nanohydrogel based on alginate–whey protein interactions
to be used as a vehicle for riboflavin. These authors ob-
served that alginate–whey protein isolate nanohydrogels
have the ability to delay the compound’s release in the
stomach and allow complete release in the small intestine.
Nanocapsules
The development of nanocapsules for the delivery of
bioactive compounds has been widely studied since the
1970s aiming at the development of nanostructures for oral
drug delivery [22, 129].
A great number of structures have been developed using
synthetic and/or natural polymers, where different
methodologies were used for their production (e.g., ionic
pre-gelation/coacervation, polymerization and dispersion
of preformed polymers) possibly influencing their main
properties [15].
Ionic pre-gelation/coacervation is based on the ability of
polyelectrolytes to cross-link in the presence of a counter-
ion (cationic or polyanionic) to form nanocapsules [15]
(see Table 1). Nanoparticles can also be directly synthe-
sized by the polymerization of monomers using various
polymerization techniques (such as emulsion and disper-
sion polymerization) [123]. In this method, the bioactive
compound is incorporated either by being dissolved in
the polymerization medium or by adsorption onto the
nanoparticles after the polymerization [151]. On the other
hand, nanoparticles could be prepared by dispersion of
preformed polymers through different techniques such as
self-assembly, nanoprecipitation, salting-out and using su-
percritical fluids [108, 130]. For example, the self-assem-
bly method involves the spontaneous formation of compact
and stable nanocapsules without the help of external
agents. Materials such as zein, chitosan and casein are
examples of polymers that can be used in this method [15]
(see Table 1).
In the last years, the main focus in the development of
nanocapsules has been the use of natural, biocompatible
and edible bio-based materials for their production. The use
of these materials brings a great number of challenges
concerning the production of nanostructures such as: dif-
ferent materials, molecular structure complexity and con-
trol of their properties (i.e., particle size, size distribution,
encapsulation efficiency and release behavior).
Two of the most studied bio-based materials for the
production of nanocapsules are chitosan and alginate, ei-
ther used as main materials or as ionic cross-linkers applied
after nanocapsule production. Das et al. [25] developed an
alginate–chitosan–pluronic composite for the delivery of
curcumin in cancer cells through ionotropic pre-gelation
followed by polycationic cross-linking—see Table 1.
In order to overcome the instability and fast release of
bioactive compounds under specific environmental condi-
tions, different methodologies have been used to tailor and
control their release (i.e., by diffusion and/or by matrix
degradation) from nanocapsules. Some of the possibilities
are as follows: cross-linking processes used in the formed
nanocapsules [115] and formation of a layer with other
material surrounding the nanocapsules [28].
Other main focus on the study of nanostructures delivery
is their bioavailability, where bioactive compounds solu-
bility, mass transfer rate and retention time in GI tract play
an important role in their successful use [1]. Some of the
methodologies pointed as possibilities to increase
bioavailability of nanocapsules are as follows: (1)
the formation of nanocapsules through the LbL technique
which allows the deposition of an outer layer on formed
nanocapsules (Fig. 3) according to the desired application
[15] and (2) the functionalization of the nanocapsules
surface for the control of cellular uptake [107].
Strategies for Enhancing Nanostructures Delivery
in GI—Absorption/Permeation Enhancers
Various strategies have been applied to enhance perme-
ation of bioactive compounds, such as (1) modification of
their surface or (2) the alternative approach where the
compounds are not chemically altered. Here the bioactive
compounds are combined with another targeting functional
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agent or with a specific formulation (e.g., micro/nanopar-
ticles), termed as absorption enhancers (AE) [8]. Therefore,
this section will be focused on the second approach, the
utilization of AE as a strategy to improve bioactive com-
pounds’ absorption.
AE, also termed as bioavailability enhancers, are func-
tional agents or formulations used to improve GI absorp-
tion of bioactive compounds by specifically facilitating
their membrane permeation [8]. In the last years, several
AE have been proposed; however their utility is often
limited by their restricted biological effect and toxicity.
Table 2 summarizes some approaches used to enhance
absorption of bioactive compounds. Among all approaches,
the use of chitosan as a AE has been extensively reviewed
[20, 89]. Moreover, plant origin compounds have been
stated as AE such as quercetin, curcumin, ginger and
niaziridin [73, 157]. Also sodium caprate has being used as
absorption-enhancing agent since it acts on TJs opening,
modulating paracellular transport of bioactive compounds
[184]. Krug et al. [80] demonstrated that caprate was able
to open the paracellular pathway of molecules up to
10 kDa, supporting the application of caprate as an effec-
tive AE.
One of the main advantages of utilizing AE for poorly
membrane-permeable compounds is the development of
non-injection formulations (i.e., oral route), which are
considered to be the most comfortable and convenient
route of administration. Moreover, from an economic point
of view, as AE will promote efficient systemic absorption,
the waste of costly compounds is likely to be reduced [7].
Although several AE have been successful used, a part
of them come with hurdles that limit their commercial use.
Table 2 Absorption enhancers used in nanostructured formulations to promote bioactive compounds intestinal absorption
Absorption enhancers Nanostructure materials Bioactive compound Outcome References
Chitosan Chitosan oligomers LMWH : LMWH intestinal absorption (via electrostatic
interactions); low toxicity
[181]
Chitosan/carboxymethyl
chitosan
DOX : DOX paracellular (by chelating Ca2?) and
transcellular (via active endocytosis) intestinal
transports
[51]
Lecithin Chitosan Melatonin : melatonin permeability [60]
Sodium taurocholate HPMC Granisetron : granisetron permeation (in vitro) than
granisetron alone; low cytotoxicity in vitro and
in vivo
[36]
CSKSSDYQC peptide Trimethyl chitosan
chloride
Insulin : insulin permeation; : insulin bioavailability
(1.5-fold higher when compared to non-
conjugated ones)
[66]
Lectin WGA and PLGA TP : TP absorption; : interaction with intestinal
membrane (1.8–4.2 fold compared with the
non-conjugated ones)
[178]
WGA Bufalin : adhesion of NPs to intestinal membrane; : oral
availability (2.7-fold improvement compared
to bufalin suspensions)
[93]
WGA, chitosan and
Poly(lactic acid)
b-galactosidase : interaction with intestinal membrane; : NPs
adhesion to intestinal mucosa for prolonged
periods ([6 h) (in vivo data)
[144]
Folic acid Soy protein Curcumin : cellular uptake (in vitro studies); no significant
toxicity
[159]
PLGA Paclitaxel : transport across intestinal membrane in vitro
(eightfold compared to free paclixatel);
membrane integrity not affect significantly
[131]
Vitamin-B12 Dextran Insulin ; blood glucose level (70–75 %) after insulin
loaded-Vitamin B12-NPs absorption (in vivo
studies)
[16]
Biotin Liposomes Insulin : insulin absorption (in vitro and ex vivo
studies); : bioavailability
[182]
b-cyclodextrin Nanosponge Paclitaxel : paclitaxel in plasma; : bioavailability (2.5-fold
higher than paclitaxel alone)
[162]
: increase, ; decrease, LMWH low-molecular-weight heparin, DOX doxorubicin hydrochloride, NPs nanoparticles, WGA wheat germ agglutinin,
PLGA poly(lactic-co-glycolic acid), HPMC hydroxypropyl methylcellulose and TP thymopentin
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For example, some AE have been demonstrated to cause
damage and irritation of intestinal mucosa [140]. Addi-
tionally, large-scale production is one of the main chal-
lenges for nanostructured AE production, mainly because it
is harder to maintain size and composition, while avoiding
agglomeration of these compounds during a scaling-up
process [73]. Despite the presented disadvantages, several
intestinal AE have registered progresses in terms of their
application, being a few already in clinical trials [8]. The
main barrier to the commercialization of AE seems to rely
on the demonstration of safety and improved biological
activity. Although this strategy may enable development of
bioactive compounds with specific biological activity, all
data indicate that AE will gradually become more broadly
accepted in food and medical markets.
Nevertheless, scarce information has been found re-
garding characterization of biopolymeric nanostructures
during the digestion process. Therefore, appropriate tech-
niques to characterize these nanostructures during the
passage through the GI tract in order to understand how
they can resist to harsh conditions and their behavior dur-
ing release of bioactive compounds to specific sites will be
highlighted.
Separation, Purification and Characterization of Bio-
Based Nanostructures Following Digestion
and Absorption
Regulation for the use of nanostructures in the food in-
dustry led to a long and hard path in order to determine
their safety for consumers. Despite the significant amount
of work developed in the last years, it is not obvious how
nanostructures behave after ingestion and digestion pro-
cesses and how they will change their characteristics/
properties after the absorption.
Several techniques and methodologies have been pre-
sented in the last years for the characterization of nanos-
tructures [e.g., dynamic light scattering, size exclusion
chromatography, confocal scanning light microscopy
(CLSM), scanning electron microscopy, transmission
electron microscopy (TEM)] being unanimous used for
virtually all types of nanostructures [90, 121]. While
characterization methodologies are established among
scientific community, separation and purification tech-
niques of nanostructures from foods, after the passage
through GI systems and in human fluids are not consensual.
Recently, the existing methods for separation, purifica-
tion and characterization of nanostructures in foods have
been summarized [12, 79, 90, 121, 179]. Also, research
projects were focused in development and validation of
screening methods for the determination of nanostructures
in food matrices [112].
It is known that nanostructures, besides food matrices,
also interact with gastric fluids, leading to a change of their
main characteristics. This change can happen due to the
interaction with proteins (e.g., changing their charge and
agglomeration state) [84] and pH values under GI condi-
tions (e.g., leading to agglomeration) [122]. Several
separation and purification methods have been explored in
the last years for the characterization of nanostructures
after ingestion, passage through GI systems and once in-
corporated in human fluids. Inorganic nanostructures (e.g.,
gold and silver) and others from synthetic materials have
been the most studied [4, 111]. However, few works de-
scribe methodologies and useful techniques for separation
and purification of bio-based nanostructures. Their unique
characteristics in terms of composition (e.g., polysaccha-
rides, proteins and lipids), shape (e.g., spherical or planar),
size (e.g., from 20 to 200 nm), charge (e.g., neutral, posi-
tive and negative) and degradability (e.g., acid or medium)
make them a challenge for analytical and chemistry sci-
ence. Thus, techniques and methodologies used should be
chosen based on their characteristics and behavior.
M-M et al. [126] used an online flow field flow frac-
tionation (FlFFF) with inductively coupled plasma mass
spectrometry (ICP-MS) for the determination of particle
size of selenium nanostructures (stabilized by pectin,
mixed alginate/pectin, ovalbumin and b-lactoglobulin)
after GI tract passage. Results showed good agreement of
particle size observed by FlFFF and the images obtained by
TEM. The stability of different kinds of polymeric micelles
(composed of polyethylene glycol (PEG), poly(lactic acid)
and Tween 80) was evaluated in human serum, using
fluorescence-based approach (Forster Resonance Energy
Transfer). Asymmetrical Flow Field Flow Fractionation
(AF4) was used for the separation of the micelles (further
characterized by light scattering) [106]. In other interesting
work, Lee et al. [84] evaluated chitosan nanostructures
integrity after GI tract passage and when in contact with a
Caco-2 cell monolayer. The disintegration degree of chi-
tosan nanostructures was determined by free chitosan
quantification (using fluorescein isothiocyanate (FITC)-la-
beled chitosan) separated through ultracentrifugation. At
the same time, nanostructure mean diameter and zeta po-
tential were determined. CLSM was used to visualize
chitosan nanostructures after their transport through Caco-2
cell monolayer allowing to understand the behavior of
these nanostructures in cells. David-Birman et al. [26]
evaluated the in vitro digestion of Lf-based nanostructures
with anionic low-methoxy pectin (LMP), high-methoxy
pectin (HMP), sodium alginate (ALG) and iota-car-
rageenan (CAR). The proteolysis products were charac-
terized by sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). These authors observed the
structures’ integrity during gastric and duodenal digestion.
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They observed that these structures coated with HMP did
not protect Lf from gastric proteolysis once intact Lf band
was not detectable even after short digestion periods. The
same authors concluded that ALG extends Lf resistance to
proteolysis beyond that of LMP. Lf intact band was de-
tected even after 40 min of gastric digestion. The digestion
experiments revealed that Lf proteolysis leads to the for-
mation of peptides, with specific SDS-PAGE bands.
However, Lf-based nanostructures were relatively persis-
tent and even reached the duodenal experiments.
It is expected that in the next few years, new studies
exploring the detection and characterization of nanostruc-
tures under different environmental conditions will be
achieved. This will allow improved traceability and eval-
uation exposure of these nanostructures to human body.
Nanotoxicity Assessment in GI Tract
The production of nanostructured systems presents an in-
creasing risk of exposure to both nano-sized systems and
associate products at concentration levels that could exceed
those naturally present in the body. In some cases, nanos-
tructure parts could be retained in the body for a long-term
period due to incomplete excretion. Consequently, it may
disturb normal functions of organs or tissues inducing
metabolic toxicity, immunotoxicity or even genotoxicity
[127]. Thus, in order to minimize and even prevent possible
health risks, potential toxicity of these nanostructures has to
be assessed in depth before their use in oral administration.
The interactions of engineered nanostructures with
biological systems and the consequent toxicity are due to
materials themselves and also to their nano-size-related
physicochemical characteristics (e.g., size, shape, aggre-
gation, charge and surface properties). For instance, Loh
et al. [94] reported that in vitro cytotoxicity of chitosan
nanostructures against Caco-2 cells is less dependent on
positive surface charges than on the particle size.
Several topics need to be addressed in studies of
nanostructures toxicity, namely dose metric, standardized
assays and reference materials, to draw general conclusions
regarding toxicity of nanostructures [10]. Also, it is crucial
to design a study by using a wide range of doses (e.g.,
doses resulting from biokinetic studies in vivo), so that a
careful analysis of the dose–response correlations can be
performed. An exposure and dose metric for engineered
nanostructures, which have a range of either chemical
compositions or structures, or even both, will depend on
the mechanism of their pharmacokinetic and toxicological
behavior [83].
Many toxicological studies (in vitro and in vivo) have
been conducted on engineered nanostructures. Neverthe-
less, the absorption, distribution, metabolism and excretion
processes of these nanostructures have not been completely
addressed and understood to date. Additionally, current
testing and toxicity studies are mainly performed using a
wide range of cell lines (e.g., Caco-2 cells), as well as
in vivo models (e.g., mice). These circumstances led to an
extensive number of tested nanostructures, experimental
designs and model systems, which consequently result on
several contradictory experimental data. Thus, standard-
ized test protocols to permit risk assessment of nanos-
tructures, especially dose thresholds, need to be regulated
and established [10, 167]. The European Food Safety
Authority (EFSA) provides a comprehensive document
with key issues to be considered. Topics addressed include
risk assessment, toxicological studies used for hazard
identification and characterization of nanomaterials and a
dose–response assessment [44].
Nanostructure small size confers a very large surface-to-
volume ratio, which could lead to some undesired results
after entering into the body. Possible nanostructure–cellu-
lar interactions may induce cytotoxicity and other physio-
logical outcomes to GI tract. For example, oxidative stress,
inflammation and immune responses (phagocytosis, com-
plement activation and recruitment of inflammatory cells)
[187], mitochondrial perturbation, ‘‘corona’’ formation
(please see ‘‘Protein corona’’ section), protein denaturation
[147], DNA damage and cell death [33, 81, 97]. Although
some of these responses could be beneficial for some
purposes, such as the activation of specific immune re-
sponses by nanostructures carrying antigens on vaccines
[128, 168], some of those could have harmful effects.
Despite the very scarce data on bio-based nanostructures’
immunological or cellular responsiveness of the GI tract,
some of the potential biological mechanisms that could
happen with these structures will be discussed.
Biological Mechanisms Induced by Nanostructures
Protein Corona
After the entry of nanostructures into the bloodstream,
potential interaction with biological molecules (e.g.,
phospholipids, DNA and serum proteins) could affect the
normal function of the body and consequently lead to
toxicity effects. The binding of a mixture of cellular pro-
teins to nanostructures forming the so-called protein corona
could change the structure, stability and dynamic behavior
of the nanostructures. This may provide different physio-
logical responses of an organism [174]. For example, the
protein corona can influence cell membrane endocytosis
and exocytosis of nanostructures, as well as promote their
uptake by phagocytes [119, 134].
The size, charge and type of coating on nanostructure
surface have a strong influence on how they are going to be
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recognized by the cells [109]. Also, whether the particles
are agglomerated or not on the biological fluids [33, 101]
could strongly modify their uptake. Moreover, nanoparti-
cles can induce conformational changes in proteins, af-
fecting their physiological function [147]. Thus, in vivo
fate of nanostructures and the biological responses could be
altered when compared with in vitro studies.
The formation of a protein corona is believed to be the
principal factor influencing its pattern of in vivo biodis-
tribution, and thus its pharmacokinetic profile. There is still
discussion on the advantages and disadvantages of ad-
sorbed proteins [10, 30]. In some circumstances, it is useful
to have these bound proteins as they can direct or target the
nanoparticles to a specific area of the body [39]. Also,
protein corona could play an important role in modulating
toxicity of nanostructures [171]. For example, Peng et al.
[119] reported that formation of a nanostructure-albumin
complex is an effective and feasible means to prolong the
nanostructure circulation time and reduce their toxicity. On
the other hand, binding of proteins has also been shown to
be correlated with rapid uptake into the liver and spleen,
and clearance of the particles by the reticuloendothelial
system [174]. This can be a negative effect if one of the
aims is to increase nanostructures circulation and the re-
tention time in the body.
However, further studies are needed to understand in-
teraction and potential impact of nanostructures with other
cellular components (e.g., polysaccharides, proteins).
Oxidative Stress
The increased production of reactive oxygen species
(ROS), revealing oxidative stress, has been proposed as a
model for the assessment of toxicity induced by nanos-
tructures [102]. High ROS levels could damage cells by
peroxidizing lipids, inducing inflammation, changing DNA
and other proteins and interfering with signaling and gene
functions [143]. Oxidative stress induced by nanostructures
is described to enhance inflammation through regulation of
redox-sensitive transcription factors comprising nuclear
factor kappa B (NFjB), activating protein 1 (AP-1), ex-
tracellular signal regulated kinases (ERK), c-Jun N-termi-
nal kinases (JNK) and p38 mitogen-activated protein
kinases pathways [3].
ROS can be originated from several sources such as in
the phagocytic cell response to foreign material, scarce
amounts of antioxidants, presence of transition metals,
environmental factors and physicochemical properties
(e.g., surface properties and size) of some nanostructures
[6, 72]. Yan et al. [177] reported two pathways for the
intracellular ROS production by nanostructures. ROS could
indirectly be produced when nanostructures disturb the
endogenous biochemical/physiological equilibrium of
cells, damaging the structure of cellular organelles, such as
mitochondria. One the other hand, ROS production de-
pends on the direct contact of nanostructures with cellular
components. Highly reactive nanoparticle surface dangling
bonds can accept electrons from electron-donor groups,
thus oxidizing cellular components.
Activation of the Immune System and Inflammation
Response
The immune response includes both innate and adaptive
defense mechanisms, which activate different cell popula-
tions. Monocytes, tissue macrophages, dendritic cells and
neutrophils are some of the cellular components of the
innate immune response. They carry out phagocytosis and
produce inflammatory mediators, ROS and antimicrobial
peptides [56]. Interaction between nanostructured systems
and the innate immune system can induce undesirable ef-
fects such as cytotoxicity or inflammation. As previously
stated, physicochemical characteristics of nanostructures
could affect the way that immune system detects and reacts
to them. The exposure of the body to ‘‘external’’ nanos-
tructured systems could lead to harmful immune (activa-
tion or suppression) actions. When in contact with the
blood, they can activate the complement system (which is a
part of the innate humoral immune response), priming the
surface of nanostructures with opsonic complement frag-
ments (C3b, iC3b) for recognition and clearance by
phagocytic cells [17, 187]. The adaptive immune response
is mediated by antigen-specific lymphocytes (T and B
cells). Both innate and adaptive immune responses can
participate with their cells and secreted products. These
humoral factors include inflammatory cytokines, e.g., in-
terleukin (IL)-1b, IL-6, interferon (INF)-c, tumor necrosis
factor-a (TNF-a) and antibodies [45]. Semete et al. [141]
studied the uptake of chitosan and PEG-coated PLGA
nanostructures and the immunological response of Balb/C
mice within 24 h of oral administration. An evaluation of
the subsequent immune reaction by analyzing secreted pro-
and anti-inflammatory cytokines concentration profile was
conducted. The expression of pro-inflammatory cytokines
IL-2, IL-6, IL-12p70 and TNF-a in plasma was found to
remain at low concentration in PLGA nanostructures
treated mice. The anti-inflammatory cytokines IL-10 and
chemokines INF-c, IL-4 and IL-5 remained at normal
levels in the PLGA-treated mice. The authors stated that
these results claim against an immunological contraindi-
cation for the oral administration of PLGA nanostructures
in mice.
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In Vitro and In Vivo Responses to Bio-Based
Nanostructures
In vitro models can generate valuable data as a pre-stage
for in vivo animal studies, therefore reducing the number
of animal tests. The use of in vitro human cell lines of
intestinal mucosa is very valuable to assess the behavior of
orally delivered nanostructures [6].
Wang et al. [172] studied in vitro the anti-colorectal
cancer activity of puerarin nanosuspensions of lecithin and
hydroxypropyl methylcellulose (HPMC) in the human
colon cancer HT-29 cell line. Cytotoxicity assay, obser-
vation of morphological changes and early apoptosis re-
vealed that puerarin nanosuspensions could significantly
enhance the in vitro anti-proliferation effect against HT-29
cells compared to the puerarin-free solution (Table 3). In
another study, Leonard et al. [85] developed a 3D inflamed
intestinal mucosa equivalent, based on the co-culture of
intestinal epithelial Caco-2 cells, blood-derived macro-
phages and dendritic cells as components of the intestinal
innate immune system (Table 3). The cells were all located
on the porous membrane of a transwell insert. Inflamma-
tion was stimulated by the inflammatory cytokine IL-1b.
The model was assayed with two different types of delivery
vehicles (polymeric PLGA nanoparticles and liposomes)
for glucocorticoid budesonide (a standard treatment for
inflammatory bowel diseases). Glucocorticoid budesonide-
loaded PLGA nanostructures showed low toxicity and good
efficacy for recovery from inflammation, as indicated by
transepithelial electrical resistance (TEER) value and pro-
inflammatory protein release quantification. Additionally,
PLGA nanoparticles only adhered to affected parts of the
GI tract. Other examples of in vitro nanotoxicity studies are
reported in Table 3.
The methods for the in vitro toxicity evaluation are
capable of providing adequate data for many bulk materi-
als. However, the in vivo interaction of nanostructures with
the biological system is much more complicated and dy-
namic. Animal models (e.g., rats and mice) would be
particularly useful to study aspects in vivo that cannot be
obtained with in vitro systems, such as toxicokinetics in the
body (i.e., absorption, distribution, metabolism and
elimination) [52]. Toxicity of nanostructures can be in-
vestigated in greater detail in animal models and with
minimal risk, time and cost compared to human clinical
trials. Although there are some in vivo toxicity data
available, most of them are related to acute or chronic
exposure to nanomaterials used on inhalation, intra-
venously or by intraperitoneal administration, and very few
after oral exposure [183]. Thus, the study of toxic effects
induced by nanomaterials on animal models using this
route is strongly needed. Feng et al. [50] investigated the
ability of polyelectrolyte complex nanoparticles (CS/
CMCS-NPs), composed of chitosan (CS) and o-car-
boxymethyl chitosan (CMCS) as a pH responsive carrier,
for the oral delivery of doxorubicin hydrochloride (DOX)
(Table 3). The in vivo test using rats further confirmed the
efficiency and safety of DOX:CS/CMCS-NPs as oral drug
delivery system. Table 3 shows selected contributions to
the in vivo studies of nanotoxicity of bio-based nanos-
tructures in the GI tract.
Despite the fact that in vitro and in vivo studies in GI
tract had been conducted, some questions and doubts per-
sist, regarding dose selection, dose metrics, assay format,
species of cells and matrices and lack of nano-relevant
controls [35]. Moreover, a high number of in vivo explo-
rations have been conducted in rodent models, which
cannot fully mimic the complexity of the human physiol-
ogy (e.g., intestine length) and human diseases [64].
Regulatory Considerations
The design of bio-based structures, through the use of
nanotechnology, for oral delivery of bioactive compounds
has been accepted by scientific community and several
industrial organizations as a possible solution for some of
the challenges faced by the food and pharmaceutical in-
dustry [15]. This technology is most commonly used to
refer to the engineering (i.e., deliberate manipulation,
manufacture, processing or selection) of materials, struc-
tures, devices and systems by controlling shape and size at
the nanometer scale with modified or new functionalities,
as compared to the same materials at macro- and mi-
croscale [15].
However, until now, there is not a globally recognized
regulatory definition of nanotechnology or related terms
(e.g., nanoscale or engineered nanomaterials). The Na-
tional Nanotechnology Initiative Program defines nan-
otechnology as the understanding and control of matter at
dimensions between approximately 1 and 100 nm, where
unique phenomena enable novel applications [49], while
Food and Drug Administration (FDA) has not established,
to date, a regulatory definition [49]. Currently, FDA de-
veloped a framework based in two major points for con-
sidering whether products include nanomaterials or
otherwise involved nanotechnology: (1) whether an engi-
neered material or end product has at least one dimension
in the nanoscale range (approximately 1–100 nm) or (2)
whether an engineered material or end product exhibits
properties or phenomena, including physical or chemical
properties or biological effects, that are attributable to its
dimension(s), even if these dimensions fall outside the
nanoscale range, up to one micrometer [49]. The European
Union (EU), through the Commission Regulation (EU)
report No 1363/2013 that replaces the report No 1169/2011
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of the European Parliament and of the Council, published
the definition of engineered nanomaterials as any inten-
tionally manufactured material containing particles in an
unbound state, or as an aggregate or agglomerate and
where, for 50 % or more of the particles in the number size
distribution, one or more external dimensions is in the size
range of 1–100 nm [42].
In terms of the current regulatory approaches in the EU,
it is generally considered that the existing regulatory
framework will cover potential uses of nanotechnologies in
the food, either by the principles of the general food law
(EC 178/2002) or by specific approval processes. Major
gaps in existing regulations were not identified in a review
undertaken by the UK Food Standards Agency [54], but
there is uncertainty in some areas as to whether a number
of specific applications of nanotechnologies would be
picked up consistently, for example, the introduction of
nanoscale preparations of existing food ingredients, or
currently approved food additives. A review recently
completed by the commission has indicated that the ex-
isting EU legislation is broadly adequate to cover potential
risks of nanotechnology-based products. Although, in some
areas, specific supporting instruments (e.g., guidelines and
standardized protocols) may be needed. Moreover, some
provisions should be clarified or adapted, in order to ensure
the full effectiveness of the existing legislation in practice
[40].
The Task Force on Novel Foods and Nanotechnology of
the European Branch of the International Life Sciences
Institute (ILSI Europe) set up an expert group to develop
practical guidance on how to approach the safety assess-
ment of products of nanotechnology. This guidance is
aimed at scientists involved in the research and develop-
ment of such products specifically for food applications.
Much of the debate on the safe use of nanotechnology for
food applications has focused on the doubts, unknowns and
lack of available information.
Engineered nanostructures, as with all materials added to
foods, are a distinct group with individual chemical, biolo-
gical, physiological, pharmacological and toxicological
profiles. Several bodies and organizations have considered
the terminology to be applied to this family of materials for
the purposes of evaluation from different perspectives [43,
48, 65], and there is still an ongoing debate to achieve
working definitions to ensure consistency [41].
Concluding Remarks
This review describes basic principles but also emerging
trends and future challenges for designing the next gen-
eration of nanostructures. As previously stated, biopoly-
meric multilayer nanostructures assembled using LbL
technique are promising candidates for more complex tasks
of protection, encapsulation and release. Thus, these
structures can be engineered and functionalized with de-
sired characteristics. However, one of the major concerns
of using engineered nanostructures in food is that there is
insufficient knowledge on how physicochemical properties
(at nanoscale) may change the biological fate of ingested
bio-based materials (even if the bulk material is the same)
and bioavailability of encapsulated bioactive compounds.
This could influence their toxicological properties and
may lead to adverse effects on human health. Evidence that
engineered nanostructures can cross natural barriers within
the body is increasing. Although the health implications of
this, if any, remain unclear and have to be linked with the
background exposure to nanostructures (e.g., proteins,
carbohydrates and fats) found naturally in food, and which
are part of human daily diet, nanoscale proteins, carbohy-
drates and fats are unlikely to be a source of toxicity in
their own right. However, scarce information is available
about the possible interactions of engineered nanostruc-
tures with components of food. Moreover, potential toxic
effects on GI tract or at systemic level, maintenance of
their integrity following passage through the digestive
system, or how they are absorbed, distributed and excreted
from the body need to be assessed.
A great number of studies focused on the development
of nanostructured systems for bioactive compounds deliv-
ery based in inorganic materials. However, few studies
have focused on bio-based nanostructures behavior fol-
lowing oral ingestion. At the present stage, a better fun-
damental understanding of the mechanisms of action of
these structures at the molecular level will provide a basis
for their further optimization to ensure design of ideal
nanocarriers. This will open more exciting opportunities
for their use in the area of bioactive compounds delivery.
While a range of in vitro screening tests have been de-
veloped, few in vivo studies in animals have been carried
out, particularly via the oral route which is the only rele-
vant route for prediction of risks in food. Therefore, it is
critical to develop predictive and validated toxicological
tests that can be used to screen potential human risks as
well as new methodologies for measurement of engineered
nanostructures in biological matrices.
The study of existing literature regarding biological ef-
fects following ingestion of bio-based nanostructures al-
lows concluding that they can modulate biological
responses. The exact determination of these effects still
remains to be clearly identified, although intrinsic physi-
cochemical characteristics of bio-based nanostructures
such as size, surface nature and dispersion state (aggrega-
tion or agglomerated) seem to be of outmost importance.
A tool that could contribute to the explanation of
nanostructures’ modes of action and potential nanotoxicity
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would be the use of toxicogenomics in combination with
traditional approaches and other—omic technologies (i.e.,
proteomics and metabolomics) [2, 125]. In particular, sys-
tems biology technology has been developed to integrate all
information at mRNA, protein and metabolite levels. This
can generate pathway information and provide the capacity
to measure subtle perturbations of pathways caused by
nanostructures [132]. For instance, the measurement of the
pattern of gene expression levels upon exposure to nanos-
tructures can provide useful information about the
mechanism of action of bio-based nanostructures [125].
Therefore, it is fundamental to understand the complex
in vitro, in vivo and in silico biological systems data inte-
gration and computational modeling. These data could al-
low risk assessment, disease prevention, diagnosis and
treatment of complex biological pathologies [55]. Addi-
tionally, fundamental advances in -omics structure–prop-
erty–process relationships (i.e., materiomics) of biological
systems contribute to the mechanistic understanding of
certain diseases and facilitate the development of novel
biomaterials for applications in nanotechnology (e.g.,
medicine and food fields) [14]. The application of these
technologies will enable a deeper understanding of bio-
chemical pathways and cellular responses to nanostructures.
Finally, the acceptance of these nanostructures in food
products by the consumer is strongly dependent on the
assurance that this novel technology is safe for human
health. Furthermore, governments and international
regulators need to promote and regulate this new tech-
nology successfully.
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